Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunogenicity After a Prime Dose and Revaccination With Adjuvanted RSVPreF3 Vaccine in the Most Elderly and Frail Population - an Open-labeled Phase IIIb-trial

NCT07203365 is registered in ClinicalTrials.gov with Karin Karin Loré as lead sponsor.

NCT NCT07203365
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07203365 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunogenicity After a Prime Dose and Revaccination With Adjuvanted RSVPreF3 Vaccine in the Most Elderly and Frail Population - an Open-labeled Phase IIIb-trial
Lead sponsor
Karin Karin Loré
Phase
Phase 3
Overall status
Active, not recruiting
Start date
August 25, 2025
Completion date
May 31, 2029
Enrollment
75 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

rsv immunisation